Residency · Residency · Neurology

Neurodevelopmental Disorders and Intellectual Disability

Introduction

Neurodevelopmental disorders encompass a group of conditions with onset during the developmental period that produce deficits in personal, social, academic, or occupational functioning. Intellectual disability (ID), autism spectrum disorder (ASD), and attention-deficit/hyperactivity disorder (ADHD) are among the most prevalent, collectively affecting 10-15% of children. The neurologist plays a critical role in etiological evaluation, identification of treatable conditions, genetic counseling, and management of neurological comorbidities such as epilepsy.

Intellectual Disability

Definition and Classification

Intellectual disability is defined by deficits in both intellectual functioning (IQ less than 70) and adaptive functioning across conceptual, social, and practical domains, with onset during the developmental period. The majority of cases, roughly 85%, fall into the mild category (IQ 50-70), where individuals can achieve functional literacy and live independently with appropriate support. Moderate ID (IQ 35-50) requires ongoing support, though affected individuals can learn basic self-care and vocational skills. Severe ID (IQ 20-35) requires substantial daily support, while profound ID (IQ less than 20) necessitates pervasive support for all activities of daily living.

Etiology

Genetic causes are identified in 40-60% of cases with modern testing. Chromosomal abnormalities represent a major category, with Down syndrome (trisomy 21) being the most common genetic cause, followed by fragile X syndrome and other aneuploidies and deletions. Copy number variants, including microdeletions and microduplications, account for another significant subset: 22q11.2 deletion (DiGeorge/velocardiofacial syndrome), Williams syndrome (7q11.23 deletion), Angelman syndrome (15q11-13), and Prader-Willi syndrome are among the most recognized. Single gene disorders such as Rett syndrome (MECP2), tuberous sclerosis (TSC1/TSC2), and fragile X (FMR1) make up the remainder, alongside hundreds of other implicated genes.

Beyond genetics, prenatal causes include congenital infections (TORCH), teratogens such as fetal alcohol spectrum disorder and valproate exposure, and malnutrition. Perinatal causes include hypoxic-ischemic encephalopathy, prematurity, and intracranial hemorrhage. Postnatal causes span meningitis and encephalitis, traumatic brain injury, lead poisoning, and severe malnutrition.

Diagnostic Evaluation

The evaluation begins with a thorough developmental history and standardized cognitive and adaptive behavior testing. First-tier genetic testing is chromosomal microarray (CMA) to detect copy number variants, with a diagnostic yield of 15-20%. If CMA is non-diagnostic, second-tier testing proceeds to whole exome sequencing (WES) or whole genome sequencing (WGS), which provides an additional yield of 25-40%. Fragile X testing (FMR1 CGG repeat analysis) should be performed in all males and females with unexplained ID. Metabolic screening for inborn errors of metabolism should be considered, especially when there is regression, organomegaly, or dysmorphic features. MRI of the brain reveals structural abnormalities in 30-40% of cases, including cortical malformations, white matter abnormalities, and cerebellar anomalies. An EEG should be obtained if seizures are suspected.

Autism Spectrum Disorder

Core Features

ASD is characterized by persistent deficits in social communication and social interaction across multiple contexts, alongside restricted, repetitive patterns of behavior, interests, or activities. Symptoms are present from early childhood, though they may not become apparent until social demands exceed the individual's capacity. Severity is specified by support needs: Level 1 (requiring support), Level 2 (requiring substantial support), and Level 3 (requiring very substantial support).

Neurological Comorbidities

Epilepsy is present in 20-30% of individuals with ASD, and the risk is highest when there is co-occurring intellectual disability, with seizure onset peaking in early childhood and adolescence. Intellectual disability co-occurs in approximately 30-40% of ASD cases. Sleep disturbances, including insomnia and circadian rhythm abnormalities, affect 50-80% of individuals. Motor abnormalities such as hypotonia, motor incoordination, stereotypies, and catatonia are also commonly observed.

Genetic Architecture

ASD is highly heritable, with heritability estimated at 80-90%. The genetic landscape is heterogeneous, with more than 100 genes identified that have strong ASD association. High-confidence ASD genes include CHD8, SHANK3, PTEN, SCN2A, SYNGAP1, and ADNP. Syndromic forms of ASD are associated with tuberous sclerosis (TSC1/TSC2), fragile X, Rett syndrome, Angelman syndrome, and Phelan-McDermid syndrome (22q13 deletion/SHANK3). The combined diagnostic yield of CMA and/or WES ranges from 10-40% depending on selection criteria.

Attention-Deficit/Hyperactivity Disorder

ADHD is a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning. It is classified into three presentations: predominantly inattentive, predominantly hyperactive-impulsive, and combined. The prevalence is 5-7% of children and 2.5% of adults, with a strong genetic component. Neuroimaging studies consistently show reduced volumes of the prefrontal cortex, basal ganglia, and cerebellum. Treatment includes behavioral interventions, stimulant medications (methylphenidate, amphetamine salts), and non-stimulants (atomoxetine, guanfacine). From a neurological standpoint, ADHD has high comorbidity with epilepsy, tic disorders, and learning disabilities.

Selected Genetic Syndromes

Down Syndrome (Trisomy 21)

Down syndrome is the most common genetic cause of intellectual disability, with an incidence of 1 in 700 live births. It presents with characteristic facies, hypotonia, and congenital heart defects, particularly atrioventricular canal defects. Neurological concerns include early-onset Alzheimer disease (with virtually universal amyloid pathology by age 40), atlantoaxial instability, epilepsy (including infantile spasms), and obstructive sleep apnea. As life expectancy in Down syndrome has increased substantially, screening for and management of dementia has become an essential part of care.

Fragile X Syndrome

Fragile X syndrome is the most common inherited cause of intellectual disability. It is X-linked and caused by a CGG repeat expansion in the FMR1 gene. Males are more severely affected, typically presenting with moderate intellectual disability, a long face, prominent ears, macroorchidism (post-pubertal), and behavioral features including anxiety, gaze avoidance, and perseverative speech. Females show a variable phenotype ranging from learning disabilities to normal cognition. An important related condition is fragile X-associated tremor/ataxia syndrome (FXTAS), a late-onset cerebellar ataxia and action tremor that develops in premutation carriers (55-200 CGG repeats). MRI in FXTAS characteristically shows middle cerebellar peduncle T2 hyperintensity.

Rett Syndrome

Rett syndrome is an X-linked dominant disorder caused by MECP2 mutations that predominantly affects females. Development is normal for the first 6-18 months, after which regression occurs with loss of purposeful hand skills (replaced by stereotypic hand wringing), loss of spoken language, gait abnormalities, and breathing irregularities. Seizures occur in 60-80% of patients, and autonomic dysfunction and scoliosis are common. Trofinetide, an IGF-1 analog, has been approved for treatment.

Management Principles

Early intervention services, including speech therapy, occupational therapy, and behavioral therapy, improve outcomes regardless of the underlying etiology. Seizure management requires appropriate antiseizure medications, with consideration of syndrome-specific recommendations. For sleep disturbances, melatonin is the first-line treatment for insomnia in ASD and ID. Behavioral management includes applied behavior analysis (ABA) for ASD and medication for severe behavioral disturbances, with risperidone and aripiprazole approved for irritability in ASD. Transition planning for adult care and services is essential, as is genetic counseling for families regarding recurrence risk and reproductive options.

Clinical Pearls

Chromosomal microarray is the recommended first-tier genetic test for unexplained ID and ASD, detecting pathogenic copy number variants in 15-20% of cases. Fragile X syndrome should always be tested for in individuals with unexplained ID, as it is the most common inherited cause and has specific implications for family members, since premutation carriers are at risk for FXTAS and primary ovarian insufficiency. Epilepsy and ASD frequently co-occur, especially when ID is present, and a low threshold for EEG evaluation is warranted in children with ASD who have developmental regression or staring spells. Genetic diagnosis in neurodevelopmental disorders is increasingly therapeutic, as identification of specific gene variants can guide syndrome-specific treatments and help avoid harmful medications. Down syndrome patients require screening for early-onset Alzheimer disease beginning at age 40, as virtually all develop amyloid pathology.

References

1. Michelson DJ, Shevell MI, Sherr EH, et al. Evidence report: genetic and metabolic testing on children with global developmental delay. Neurology. 2011;77(17):1629-1635.
2. Srivastava S, Love-Nichols JA, Dies KA, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019;21(11):2413-2421.
3. Lord C, Brugha TS, Charman T, et al. Autism spectrum disorder. Nat Rev Dis Primers. 2020;6(1):5.
4. Hagerman RJ, Berry-Kravis E, Hazlett HC, et al. Fragile X syndrome. Nat Rev Dis Primers. 2017;3:17065.

Read this lecture as Markdown